We have put together a list of popular science video lectures on gene therapy – one of the most promising molecular medicine directions. What makes this approach different is that nucleic acid molecules, DNA and RNA, are used as therapeutic agents.
To have the most general idea about the principles of gene therapy you can watch this video
The lecture by Dr. Hans-Peter Kiem from Fred Hutchinson Cancer Research Center at University of Washington provides more detailed information about the main approaches utilized by gene therapy, nucleic acid delivery methods into the cells and also the diseases that use gene therapy for treatment
I have just read a very interesting paper on personalized cancer genome sequencing. I think this is a crucial topic in fighting cancer at the moment. There is more and more research data that can be translated into clinic and more and more papers talk about the relevance of personalized oncology. This review is called “Harnessing Massively Parallel sequencing in Personalized head and neck Oncology“. It has a nice picture that explains why it is a good idea to sequence your cancer genome and compare it to the genome of normal tissue. The article gives examples when next generation sequencing provided very useful data to the patients. Anyway, here is the abstract:
Advances in the management of patients with head and neck squamous cell carcinoma (HNSCC) have not significantly changed the prognosis of this tumor over the past five decades. Molecular heterogeneity of HNSCC and its association with HPV, in addition to the increase in the number of cancers arising in traditionally low-risk patients, are among some of the obstacles to the successful management of this group of tumors. Massively parallel sequencing, otherwise known as next-generation sequencing (NGS), is rapidly changing conventional patient management by providing detailed information about each patient’s genome and transcriptome. Despite major advances in technology and a significant reduction in the cost of sequencing, NGS remains mainly limited to research facilities. In addition, there are only a few published studies that have utilized this technology in HNSCC. This paper aims to report briefly on current commercially available NGS platforms and discuss their clinical applications, ethical considerations, and utilization in personalized patient care, particularly as this relates to head and neck cancer.
We all know how competitive Craig Venter is. Last time he won in the race against the Human Genome Project participants, and now he is up against Google’s Calico. Together with Peter Diamandis and Robert Hariri he co-founded Human Longevity, a company that aims to scan the DNA of as many as 100,000 people a year to create a massive database that will lead to new tests and therapies to help extend healthy human life spans.
Human Longevity has an agreement with the University of California at San Diego to perform genome sequencing of patients at the Moores Cancer Centre. In addition to providing DNA data to doctors at the university, the goal is to make individual genome data directly available to patients once the company meets US regulatory standards for providing clinical-level information. In addition to genome and microbiome data, the company will collect data on biochemicals and lipids circulating throughout patients’ bodies.
This sounds like a plan. The thing that Calico hasn’t got yet. Or at least hasn’t announced yet. I believe in Dr. Venter and I like his plan – gathering as much information about a person’s biological data and applying it to cure age-related diseases is a great goal. They are not saying anything about aging per se, but I’m pretty sure the data will speak for itself and at some point of time the researchers will realize they are dealing with different mechanisms of aging. So yay! for a very particular, very solid step towards defeating aging.
This chart says that old stem cells, that give birth to blood cells, have much much more Wnt5a protein than the young stem cells. The canonical Wnt signaling cascade changes to the non-canonical one that produces more Wnt5a product. This observation was done by a group of scientists at the universities of Ulm and Muenchen, Germany and was published in Nature. So, why is this such a special observation?
Well, because it gives us a clue to what can be done to rejuvenate our blood producing stem cells. We can “turn off” the Wnt5a gene and make the old stem cells young again, which was successfully done by the authors of the experiment. The researchers took the short hairpin RNA and inserted it into the stem cells using a lentivirus. This hairpin RNA blocks translation of the Wnt5a protein sort of like a blank plug. So, these cells were transplanted into mice and those mice showed improved B lymphopoiesis and peripheral blood differentiation profile overall more similar to the one characteristic of young mice. This can one day become a therapy for humans. We could periodically receive such transplantations of our own hematopoietic stem cells, rejuvenated using gene therapy and we could have young blood production again.
Dr. Reis talks about the main trends in longevity research, potential for creation life extension therapies in the nearest future, his favorite genes, preferable ratio of basic to applied research funding and the overall hurdles of aging research field.
Figure 1. In the absence of insulin or growth factors, FOXO transcription factors are located in the nucleus, where they specify target gene expression (see text for details).
Knowing what kind of genes are involved in the main biological processes is much more relevant to your life than which car is faster, Porsche or Jaguar. And I’m not talking about dangerous driving here. I am talking about the crucial information about the genes that govern your longevity. You have to know what they are, what they do, what happens to them during aging and what are the ways to make them work better, towards keeping you young for a longer time. I am reprinting the text of the article written by Dr. Matthew Carter and Dr. Anne Brunet from Stanford University. I let myself explain some of the biological terms in brackets to make this beautifully written story of one gene a bit simpler. This is a must-read.
FOXO transcription factors
What are they? FOXO proteins are a subgroup of the Forkhead family of transcription factors (proteins that can bind to DNA and “switch on” other genes) . This family is characterized by a conserved DNA-binding domain (the ‘Forkhead box’, or FOX) and comprises more than 100 members in humans, classified from FOXA to FOXR on the basis of sequence similarity. These proteins participate in very diverse functions: for example, FOXE3 is necessary for proper eye development, while FOXP2 plays a role in language acquisition. Members of class ‘O’ share the characteristic of being regulated by the insulin/PI3K/Akt signaling pathway (a chain of reactions within a cell that is the response to a signaling molecule attaching to a receptor on the surface of the cell).
How did this family get named ‘Forkhead’? Forkhead, the founding member of the entire family (now classified as FOXA), was originally identified in Drosophila as a gene whose mutation resulted in ectopic (meaning unusual) head structures that looked like a fork. Forkhead proteins are also sometimes referred to as ‘winged helix’ proteins because X-ray crystallography revealed that the DNA-binding domain features a 3D structure with three α-helices flanked by two characteristic loops that resemble butterfly wings.
How many FOXOs are there? In invertebrates, there is only one FOXO gene, termed daf-16 in the worm and dFOXO in the fly. In mammals, there are four FOXO genes, FOXO1, 3, 4, and 6.
Hey, what about FOXO2 and FOXO5? FOXO2 is identical to FOXO3 (a.k.a. FOXO3a, as opposed to FOXO3b, a pseudogene, dysfunctional relative of a gene, unable to produce protein). FOXO5 is the fish ortholog (genetic analog) of FOXO3.
FOX hunting… FOXO genes were first identified in humans because three family members (1, 3, and 4) were found at chromosomal translocations (errors) in rhabdomyosarcomas and acute myeloid leukemias. Just after FOXO factors were identified in human tumor cells, the crucial role of DAF-16 in organismal longevity was discovered in worms. DAF-16 activity was shown to be negatively regulated by the insulin/PI3K/Akt signaling pathway (the pathway that provides cellular response to insulin). Subsequent experiments in mammalian cells showed that mammalian FOXO proteins were directly phosphorylated (a phosphate was bound) and inhibited (suppressed) by Akt in response to insulin/ growth factor stimulation. Thus, FOXO factors are evolutionarily conserved mediators of insulin and growth factor signaling (meaning they are present in the majority of animals throughout the evolutionary tree from simple species like worms to humans).
Why are they important? FOXO transcription factors are at the interface of crucial cellular processes, orchestrating programs of gene expression (production of proteins) that regulate apoptosis (cellular programmed death), cell-cycle progression, and oxidative- stress resistance (Figure 1). For example, FOXO factors can initiate apoptosis by activating transcription of FasL, the ligand for the Fas-dependent cell-death pathway, and by activating the pro-apoptotic Bcl-2 family member Bim. Alternatively, FOXO factors can promote cell-cycle arrest (it’s when the cell can’t continue its life path, stops dividing); for example, FOXO factors upregulate (increase production of dependent proteins) the cell-cycle inhibitor p27kip1 to induce G1 arrest (a point of time in the cell-cycle when the cell needs to check whether its DNA has no errors, and if it doesn’t, it can go on to the next stage of development) or GADD45 to induce G2 arrest (point of time when the cell checks if it has any DNA errors after replication, and if it doesn’t it can start mitosis). FOXO factors are also involved in stress resistance via upregulation of catalase and MnSOD, two enzymes involved in the detoxification of reactive oxygen species. Additionally, FOXO factors facilitate the repair of damaged DNA by upregulating genes, such as GADD45 and DDB1. Other FOXO target genes have been shown to play a role in glucose metabolism, cellular differentiation, muscle atrophy, and even energy homeostasis.
How are they regulated? FOXO proteins are tightly regulated to ensure that transcription (first step in protein synthesis) of specific target genes is responsive to environmental conditions. A major form of regulation is Akt-mediated phosphorylation of FOXO in response to insulin or growth factors (Figure 1). Phosphorylation at three conserved residues results in the export of FOXO factors from the nucleus to the cytoplasm, thereby inhibiting FOXO-dependent transcription. FOXO proteins are also phosphorylated by other protein kinases, including JNK or Mst1, which phosphorylate FOXO under conditions of oxidative stress. This phosphorylation causes the translocation of FOXO from the cytoplasm to the nucleus, thus opposing Akt’s action. In addition to being post-translationally modified by phosphorylation, FOXO proteins also bind to co-activator or co-repressor complexes and become acetylated or deacetylated (process of adding or removing the acetyl group). For example, the deacetylase SIRT1 increases FOXO DNA-binding ability by deacetylating FOXO in response to oxidative stress. FOXO proteins are also monoubiquitinated (added one ubiquitin group) under conditions of oxidative stress and this increases transcriptional activity. Finally, FOXO proteins can also be polyubiquitinated and targeted for protein degradation. The unique phosphorylation, acetylation, and ubiquitination status of FOXO under specific environmental conditions may provide specificity in the regulation of subsets of FOXO target genes.
What is the role of FOXO in longevity? FOXO factors have been shown to prolong lifespan in invertebrates. The worm orthologue, DAF-16, activates a program of genes that extend longevity by promoting resistance to oxidative stress, pathogens, and damage to protein structure. Mutations in the insulin receptor or PI3K extend longevity up to threefold, and this extension is reverted when daf-16 is mutated. In flies, overexpression of dFOXO is sufficient to increase longevity. The role of FOXO factors in mammalian longevity is currently being explored. Mice that are deficient for either the insulin receptor or the insulin-like growth factor receptor-1 can live up to 30% longer than wild-type mice, suggesting that FOXO factors could be involved in mammalian longevity. Furthermore, FOXO target genes involved in stress resistance are conserved between invertebrates and mammals, suggesting that the function of FOXO in organismal stress resistance and longevity is evolutionarily conserved.
Isn’t it strange that FOXO could induce both stress resistance and cell death? The regulation of stress-resistance genes and pro-apoptotic genes by FOXO is not necessarily a paradox. FOXO factors may orchestrate different patterns of gene expression based on the intensity of the stimulus, perhaps activating stress-resistance genes under mild conditions but pro-apoptotic genes when the intensity of stress stimuli increases beyond a certain threshold. It is also possible that FOXO factors regulate different genes in different cell types, causing apoptosis in some cells (e.g. neurons, lymphocytes) while promoting survival in others. Importantly, the induction of apoptosis by FOXO may cause the death of damaged or abnormal cells, therefore benefiting the longevity of the entire organism.
Is there a connection between FOXO and cancer? Because FOXO proteins were originally identified in human tumors, and because they play an important role in cell-cycle arrest, DNA repair, and apoptosis — cell functions that go awry in cancer — the FOXO family is thought to coordinate the balance between longevity and tumor suppression. Consistent with this idea, in certain breast cancers, FOXO3 is sequestered in the cytoplasm and inactivated. Expression of active forms of FOXO in tumor cells prevents tumor growth in vivo. Additionally, protein partners of FOXO, such as p53 and SMAD transcription factors, are tumor suppressors. Investigating the ensemble of FOXO protein partners will provide insight into the connection between aging and cancer.
Can you live without FOXO? It depends if you are a worm, a fly, or a mammal. Worms lacking daf-16 or flies lacking dFOXO are viable but do not show an increase in lifespan following mutations in the insulin/PI3K/Akt pathway. FoxO1-null mice (mutants that have no FoxO1 gene) die at embryonic day 10.5 from defects in angiogenesis. FoxO3- and FoxO4-null mice have also been produced and are viable: FoxO3-null mice exhibit an age-dependent infertility in females, while FoxO4-null mice have no apparent phenotype. FoxO6-null mice are currently being generated. The four mammalian isoforms (different form of a protein) may have both distinct and overlapping functions, and compensation of one member by another may mask the function of individual FOXOs. Investigating the role of FOXO factors in longevity and tumor suppression will require more complex mouse models in which multiple FoxO genes are deleted.
What remains to be explored? More FOXO target genes remain to be discovered, as do regulators of FOXO function. An exciting area of future exploration will be to determine how FOXO factors mediate cell non-autonomous processes in the entire organism. The recent discovery that FOXO can upregulate neuropeptides in the hypothalamus suggests that FOXO can regulate animal behavior, and future studies will elucidate how hormones and neuronal signaling cause FOXO- dependent transcription of target genes that affect the entire organism.
$10 million Archon Genomics X PRIZE will be awarder to the first company to sequence 100 genomes in 30 days. Not just regular genomes, but the most fascinating – the ones that come from centenarians, people who are 100 years and older. Read the article by CNN about Peter Diamandis and the X PRIZE Foundation. I agree that it is extremely useful to identify the genetic differences and commonalities among the centenarians, yet what I find even more interesting is combining their genomic data with their medical data and also with even more comprehensive tests, such as epigenome, transcriptome, proteome and metabolome analyses. This type of “hardcore scientific testing” will provide quite a lot of insights into the reasons why these people manage to overcome the diseases of old age and stay relatively fit until 100 years and more. Only this type of testing will give enough data to figure out the longevity traits and causal relations between the traits and genomic data. By the way, once the sequencing prices drop under $1000 all the other analyses would cost not a lot more than that.
Geneticist Elizabeth Worthey worked on the first-ever treatment of a patient based on DNA sequencing, helping doctors decide to give a bone marrow transplant to a 6-year-old boy who had suffered through more than a hundred operations. Now Worthey, an assistant professor at the Medical College of Wisconsin, is part of a team working to comb through the sequences of five more children.
Every Friday, she and her colleagues at Wisconsin Children’s Hospital meet to go over cases that other doctors have put forward for DNA sequencing. There have been about three dozen requests. An insurance company has even agreed to pay for one of the cases, although the money is not yet in the bank and the hospital will not disclose either the insurer or details about the patient. This is the first time that an insurer is known to have agreed to pay for the sequencing of an entire human genome!
“For some of these kids there is no alternative,” Worthey says, “You either guess, you do nothing, or you do something — in this case, sequence their genome.”
Dr. Jaime Guevara has been studying the Laron Dwarfs for 25 years, for the last decade he has been collaborating with Dr. Valter Longo, a well-known researcher on aging at the University of Southern California. This week the two men released the findings of the research in the Science Translational Medicine Journal.
Laron Dwarfs carry mutations in the growth hormone receptor (GHR) gene that lead to severe GHR and IGF-1 (insulin-like growth factor–1) deficiencies. These mutations offer them protection from cancer and diabetes. A 22 year study of the Larons has confirmed that none has ever had diabetes and only one had cancer and that cancer was not lethal. In contrast, the study looked at 1,600 normal-height relatives who live in the same towns and found that despite similar lifestyles 5 percent got diabetes and 17 percent got cancer.
It is more or less clear what we should do in order to defeat aging. I’d like to bring to your attention a research plan in genetic and epigentic regulation. The author is Professor Alexey Moskalev. But there’s a question to which I don’t know the answer – how can one get the funding?
Download pdf – Methods of studying and interventions in genetic and epigenetic processes